LT Lexeo Therapeutics, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)Follow the Lexeo Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €404.5m. The latest transaction was reported on 18 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Townsend Richard Nolan. Every trade is openly available.
€457,907
24 ops.
Sell Volume
Analyst consensus: bullish or bearish? Analysts rate Lexeo Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$20.30.
Buys €100,050 €457,907 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
All Executives72 Thresholds0 Prospectus0 Other0
Declarations 72 total
● Officer · Executives · 18 Aug 2026
4,117 shares @ US$4.9071 0.0050% mcap 48.8% of flow Common SEC144:0001959173-26-006152
● Officer · Executives · 18 Aug 2026
1,304 shares @ US$4.9571 0.0016% mcap 6.2% of flow Common SEC144:0001959173-26-006153
● Officer, Director · Executives · 18 Aug 2026
3,345 shares @ US$4.9512 0.0041% mcap 2.5% of flow Common SEC144:0001959173-26-006154
● Officer · Executives · 1 Jul 2026
22,306 shares @ US$4.4241 0.027% mcap 100.0% of flow Common SEC144:0001959173-26-005032
● Officer, Director · Executives · 1 Jul 2026
25,947 shares @ US$4.4778 0.032% mcap 18.1% of flow Common SEC144:0001959173-26-005031
● Officer · Executives · 1 Jul 2026
4,641 shares @ US$4.485 0.0057% mcap 100.0% of flow Common SEC144:0001959173-26-005033
● Officer · Executives · 1 Jul 2026
4,666 shares @ US$4.4833 0.0057% mcap 21.7% of flow Common SEC144:0001959173-26-005036
◆ Chief Medical Officer · Executives · 29 Jun 2026
55,000 shares Common Stock SEC:0002109299-26-000007:0
▼ Chief Medical Officer · Executives · 1 Jul 2026
22,306 shares Common Stock SEC:0002109299-26-000007:1
▼ Chief Executive Officer · Executives · 6 Apr 2026
55,000 shares @ US$5.6934 72.8% of flow Common Stock SEC:0001995218-26-000009:0
◆ Chief Operating Officer · Executives · 13 Mar 2026
5,930 shares @ US$2.644 35.1% of flow Common Stock SEC:0002024096-26-000007:0
◆ Chief Executive Officer · Executives · 13 Mar 2026
2,623 shares @ US$2.644 1.5% of flow Common Stock SEC:0001995218-26-000006:0
▼ Chief Operating Officer · Executives · 18 Feb 2026
3,016 shares @ US$6.3972 24.5% of flow Common Stock SEC:0002024096-26-000005:0
▼ Chief Operating Officer · Executives · 18 Nov 2025
721 shares @ US$9.27 8.7% of flow Common Stock SEC:0002024096-26-000004:0
▼ Chief Executive Officer · Executives · 18 Feb 2026
10,173 shares @ US$6.382 11.8% of flow Common Stock SEC:0001995218-26-000004:0
◆ Chief Medical Officer · Executives · 13 Feb 2026
49,500 shares 0Common Stock SEC:0002109299-26-000004:0
◆ Chief Financial Officer · Executives · 4 Feb 2026
44,665 shares 0Common Stock SEC:0002083206-26-000002:0
◆ Chief Operating Officer · Executives · 4 Feb 2026
65,000 shares 0Common Stock SEC:0002024096-26-000002:0
◆ Chief Executive Officer · Executives · 4 Feb 2026
161,665 shares 0Common Stock SEC:0001995218-26-000002:0
▼ Chief Legal Officer · Executives · 18 Nov 2025
549 shares @ US$9.27 14.4% of flow Common Stock SEC:0001995009-25-000005:0
▼ Chief Technical Officer · Executives · 18 Aug 2025
721 shares @ US$9.27 12.9% of flow Common Stock SEC:0002024096-25-000005:0
▼ Chief Development Officer · Executives · 18 Nov 2025
386 shares @ US$9.27 12.1% of flow Common Stock SEC:0002009350-25-000005:0
▼ Chief Executive Officer · Executives · 18 Nov 2025
1,127 shares @ US$9.27 2.2% of flow Common Stock SEC:0001995218-25-000007:0
▼ Chief Medical Officer · Executives · 18 Nov 2025
615 shares @ US$9.27 26.2% of flow Common Stock SEC:0001994972-25-000005:0
◆ Chief Technical Officer · Executives · 15 Oct 2025
5,940 shares 0Common Stock SEC:0002024096-25-000003:0
25 of 72 declarations
Load more (47 remaining) 关于 Lexeo Therapeutics, Inc. Lexeo Therapeutics, Inc. 是一家专注于开发罕见遗传病基因疗法的公司。它强调 DNA 治疗解决方案的创新。